MOR MorphoSys Corp Company Cash on Hand

Official company branding of MorphoSys AG (MOR)

MorphoSys AG relies on the HuCAL and Ylanthia ecosystem, creating a strong lock-in for third-party developers to its protein libraries. The cash position, indicated by 0.68, links this potential to robotic complexes that autonomously conduct thousands of tests. Patents for myelofibrosis and support from a Swiss giant have formed a powerful technological moat, protecting the company from new startups.

Company Liquid Assets: MorphoSys Corporation (MOR) for 07/04/2022 - 08/10/2024

Analytical breakdowns for MorphoSys AG

- stock value and consensus price forecast:
Initial company analysis:MOR morphosys.com
Brand item of morphosys.com

This indicator reflects the actual volume of liquid assets, allowing for an assessment of the business's operational resilience outside the framework of quarterly reporting. By analyzing the free cash flow chart, an investor can observe real-time capital dynamics. The metric aggregates balances in current accounts and cash equivalents, subtracting current liabilities. For MorphoSys AG (MOR), this reserve is critically important during the joint promotion of pelabresib with Novartis. Sufficient cash levels ensure the uninterrupted funding of clinical trials until the commercial launch of the therapy.

Competitors of MorphoSys AG

Company Cash Volume ONC|HALO - Company Cash Reserve|Revolution Medicines - Company Cash on Hand|Company Cash Volume Ascentage Pharma AAPG|CGON - Company Cash Funds|Company Total Cash Volume URGN|BCAX: Company Cash Volume|PSNL - Company Liquid Assets|ERAS (Erasca Inc) - Company Cash Volume|Company Cash Reserve Delcath Systems Inc DCTH|Company Cash Funds YmAbs (YMAB)|Company Liquid Assets Aura Bio|Company Cash Volume CADL (Candel Therapeutics Inc.)|accuray.com (ARAY) - Company Cash Reserve|SELLAS Life Sciences Group - Company Cash Volume|ACTU - Company Cash Volume|CTOR: Company Cash Volume|Company Cash Reserve TuHURA (HURA)|TARA (Protara Therapeutics Inc) - Company Cash Volume|Fate Therapeutics, Inc. (FATE) - Company Liquid Assets|Company Cash on Hand WHWK (Aadi Bioscience, Inc.)|Company Liquid Assets TScan Therapeutics, Inc.|Company Cash Volume CSBR (Champions Oncology Corp)|Company Total Cash Amount XBIT (XBiotech USA)|CVM - Company Cash Funds|Company Cash Balance OSTX (ostherapies.com)|Radiopharm Theranostics Ltd (RADX) - Company Cash Funds|ARTV: Company Total Cash Amount|ANL (adlainortye.com) - Company Cash Volume|VERU: Company Cash Balance|Company Cash on Hand TPST (Tempest Tx)|Company Cash on Hand Xilio XLO|Company Cash Volume RENB (Renovaro)|Company Cash Volume Mural Bio MURA|Kairos Pharma Ltd - Company Cash Volume|OnKure Therapeutics (OKUR) - Company Cash on Hand|GDTC: Company Cash Volume|Curis Inc. - Company Cash Balance|Company Cash Funds apollomicsinc.com|THAR: Company Cash Balance|Company Cash Funds Advanced Biomed Corp (ADVB)|GNPX (Genprex, Inc) - Company Cash Balance|Company Cash Volume CLDI (Calidi Biotherapeutics)|sunshinebiopharma.com (SBFM) - Company Cash Reserve|Xenetic Bio - Company Cash Volume|SLRX (Salarius Pharmaceuticals, Inc.) - Company Cash and Cash Equivalents|PPBT: Company Cash Volume|Company Cash on Hand American Oncology Network Inc|BGNE (beigene.com) - Company Cash Volume|Company Cash and Cash Equivalents CKPT (Checkpoint Therapeutics)|Company Cash on Hand ELEV (Elevation Oncology Inc.)|iCAD - Company Cash and Cash Equivalents|Ikena Oncology Inc. - Company Cash on Hand|Notable Labs Corp (NTBL) - Company Cash Reserve|VIRX: Company Cash on Hand|NAYA - Company Cash Volume|Ascentage Pharma (AAPGV) - Company Cash Funds